Lipoic acid in secondary progressive MS: A randomized controlled pilot trial

Rebecca Spain; Katherine Powers; Charles Murchison; Elizabeth Heriza; Kimberly Winges; Vijayshree Yadav; Michelle Cameron; Ed Kim; Fay Horak; Jack Simon; Dennis Bourdette

doi:10.1212/NXI.0000000000000374

Full PDF

Citation

Permissions

Comment

Downloads

2911

Article Figures & Data

Figures

Tables
Additional Files

Download figure

Open in new tab

Download powerpoint

Figure 1 2010 CONSORT flow diagram
Download figure

Open in new tab

Download powerpoint

Figure 2 Differences in brain atrophy at 2 years between LA and control cohorts
Annualized percent change brain volume (PCBV) between LA and placebo cohorts using intention-to-treat analysis of 51 participants with secondary progressive MS (A). Two-year PCBV from study completers is shown and demonstrates significantly less PCBV in the LA cohort (n = 22, −0.45% [SEE 0.71]) than controls (n = 24, −1.31% [SEE 1.10], p = 0.001, B). LA = lipoic acid; SEE = standard errors of the coefficient estimate.

Additional Files

Figures
Tables

Data Supplement

Files in this Data Supplement:

Appendix e-1 - Microsoft Word file
Appendix e-2 - Microsoft Word file
Table e-1 - Microsoft Word file

Letters: Rapid online correspondence

No comments have been published for this article.

Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

Stay timely. Submit only on articles published within the last 8 weeks.
Do not be redundant. Read any comments already posted on the article prior to submission.
200 words maximum.
5 references maximum. Reference 1 must be the article on which you are commenting.
5 authors maximum. Exception: replies can include all original authors of the article.
Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose comment

Title *

Author Information

NOTE: The first author must also be the corresponding author of the comment.

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Publishing Agreement

I, the first and corresponding author, verify that I have read the contents of the PUBLISHING AGREEMENT form. *

I, the first and corresponding author, verify my disclosures and those of my co-authors are up to date at http://submit.nn.neurology.org. *

Select only one of the three options below: *

I am an Author of this Work, and the Work was prepared on my own time - not as part of my duties as an employee.

I prepared (or cooperated in the preparation of) the Work as part of my duties as an employee, and the Work is, therefore, a "work made for hire", as defined by the United States Copyright Act of 1976, as amended.

I prepared (or participated in the preparation of) the Work as part of my official duties as an officer or employee of the United States Government.

NOTE: All contributors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.

Competing interests? *

Yes

Please describe the competing interests

Main menu

User menu

Search

Lipoic acid in secondary progressive MS

A randomized controlled pilot trial

Citation Manager Formats